Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?

Background: We aimed to compare the established metabolic response criteria PERCIST and EORTC for their applicability and predictive value in terms of clinical response assessment early after the initiation of lenvatinib therapy in patients with metastatic radioiodine-refractory (RAI) thyroid cancer...

Full description

Bibliographic Details
Main Authors: Gundula Rendl, Gregor Schweighofer-Zwink, Stefan Sorko, Hans-Jürgen Gallowitsch, Wolfgang Hitzl, Diana Reisinger, Christian Pirich
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
F-18 FDG PET/CT
radioiodine-refractory differentiated thyroid cancer
tyrosine kinase inhibitor
lenvatinib
metabolic response
Online Access:https://www.mdpi.com/2072-6694/14/8/1868

Similar Items

Similar Items